Chengchi Chao

Title: Chengchi Chao: Innovator in T Cell Receptor Development

Introduction

Chengchi Chao is a notable inventor based in Shenzhen, China. He has made significant contributions to the field of immunology through his innovative work on T cell receptors. His research focuses on enhancing the recognition of specific epitopes, which is crucial for effective drug development.

Latest Patents

Chao holds a patent for the MART-1 (27-35) epitope-specific T cell receptor. This patent describes a T cell receptor that comprises an α chain and a β chain. The α chain includes three complementary determining regions, with specific sequences located at positions 61-66, 84-89, and 124-136 of SEQ ID No. 3. The β chain also contains three complementary determining regions, with amino acid sequences at positions 46-50, 68-73, and 112-125 of SEQ ID No. 4. A T cell expressing this TCR can effectively recognize a MART-1 (27-35) epitope polypeptide supported on a T2 cell and secrete IFN-γ, demonstrating the functionality of the receptor. This innovation has the potential to facilitate effective drug development when used with relevant drug targets.

Career Highlights

Chengchi Chao is currently employed at BGI Shenzhen, a leading genomics company. His work at BGI Shenzhen allows him to collaborate with other experts in the field and contribute to groundbreaking research in immunology and drug development.

Collaborations

Chao has worked alongside notable colleagues such as Fei Wang and Bo Li. Their collaborative efforts have further advanced the research and application of T cell receptors in therapeutic settings.

Conclusion

Chengchi Chao's contributions to the field of immunology through his patent on the MART-1 epitope-specific T cell receptor highlight his innovative spirit and dedication to advancing medical science. His work at BGI Shenzhen and collaborations with esteemed colleagues underscore the importance of teamwork in achieving significant breakthroughs.